| REVIEW ARTICLE |
|
| Year : 2012 | Volume
: 28
| Issue : 2 | Page : 123-128 |
|
|
Testosterone replacement and prostate cancer
Ranjith Ramasamy, Erik S Fisher, Peter N Schlegel
Department of Urology, New York - Presbyterian Hospital, Weill Cornell Medical College, New York, USA
Correspondence Address:
Ranjith Ramasamy
Department of Urology, Weill Cornell Medical College, 525 East 68th St, Starr 900, New York, NY 10065
USA
DOI: 10.4103/0970-1591.98449
|
|
|
This article is intended as a review of the available clinical data outlining the risks and benefits of testosterone (androgen) replacement therapy, specifically addressing the issue of the relationship between exogenous androgen administration and prostate cancer risk. There is controversy over whether androgen replacement is a risk factor for incident prostate cancer. Our review of current clinical information revealed that to date, no study or review has definitively shown that androgen replacement therapy is an independent risk factor for development of prostate cancer. Androgen administration seems to be beneficial in decreasing fatal cardiovascular events, body fat mass, and insulin resistance. Overall, the current clinical data seems to suggest that androgen replacement is an appropriate therapeutic option for men with symptomatic hypogonadism provided that patients continue to receive regular prostate screenings. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
